Literature DB >> 11556838

Angiogenesis is an independent prognostic factor in malignant mesothelioma.

J G Edwards1, G Cox, A Andi, J L Jones, R A Walker, D A Waller, K J O'Byrne.   

Abstract

Angiogenesis is essential for tumour growth beyond 1 to 2 mm in diameter. The clinical relevance of angiogenesis, as assessed by microvessel density (MVD), is unclear in malignant mesothelioma (MM). Immunohistochemistry was performed on 104 archival, paraffin-embedded, surgically resected MM samples with an anti-CD34 monoclonal antibody, using the Streptavidin-biotin complex immunoperoxidase technique. 93 cases were suitable for microvessel quantification. MVD was obtained from 3 intratumoural hotspots, using a Chalkley eyepiece graticule at x 250 power. MVD was correlated with survival by Kaplan-Meier and log-rank analysis. A stepwise, multivariate Cox model was used to compare MVD with known prognostic factors and the EORTC and CALGB prognostic scoring systems. Overall median survival from the date of diagnosis was 5.0 months. Increasing MVD was a poor prognostic factor in univariate analysis (P = 0.02). Independent indicators of poor prognosis in multivariate analysis were non-epithelial cell type (P = 0.002), performance status > 0 (P = 0.003) and increasing MVD (P = 0.01). In multivariate Cox analysis, MVD contributed independently to the EORTC (P = 0.006), but not to the CALGB (P = 0.1), prognostic groups. Angiogenesis, as assessed by MVD, is a poor prognostic factor in MM, independent of other clinicopathological variables and the EORTC prognostic scoring system. Further work is required to assess the prognostic importance of angiogenic regulatory factors in this disease. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556838      PMCID: PMC2375086          DOI: 10.1054/bjoc.2001.1997

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  53 in total

1.  Vascular endothelial growth factor platelet counts, and prognosis in renal cancer.

Authors:  K J O'Byrne; N Dobbs; D Propper; K Smith; A L Harris
Journal:  Lancet       Date:  1999-05-01       Impact factor: 79.321

2.  Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression.

Authors:  S Kumar-Singh; J Weyler; M J Martin; P B Vermeulen; E Van Marck
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

Review 3.  Advances in the treatment of malignant pleural mesothelioma.

Authors:  D H Sterman; L R Kaiser; S M Albelda
Journal:  Chest       Date:  1999-08       Impact factor: 9.410

4.  Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.

Authors:  S Kumar-Singh; W Jacobs; K Dhaene; B Weyn; J Bogers; J Weyler; E Van Marck
Journal:  J Pathol       Date:  1998-11       Impact factor: 7.996

Review 5.  Marimastat (BB2516): current status of development.

Authors:  W P Steward
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

Review 6.  Tumour vasculature as a target for anticancer therapy.

Authors:  M M Eatock; A Schätzlein; S B Kaye
Journal:  Cancer Treat Rev       Date:  2000-06       Impact factor: 12.111

Review 7.  New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.

Authors:  J M Cherrington; L M Strawn; L K Shawver
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

8.  Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.

Authors:  H Schouwink; C M Korse; J M Bonfrer; A A Hart; P Baas
Journal:  Lung Cancer       Date:  1999-07       Impact factor: 5.705

Review 9.  Therapeutic potential of the anti-angiogenesis drug TNP-470.

Authors:  P Gervaz; C Fontolliet
Journal:  Int J Exp Pathol       Date:  1998-12       Impact factor: 1.925

10.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

Authors:  Y Ohta; V Shridhar; R K Bright; G P Kalemkerian; W Du; M Carbone; Y Watanabe; H I Pass
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  23 in total

1.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.

Authors:  Linda L Garland; Kari Chansky; Antoinette J Wozniak; Anne S Tsao; Shirish M Gadgeel; Claire F Verschraegen; Marco A Dasilva; Mary Redman; David R Gandara
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

Review 3.  The role of interleukin-6 in malignant mesothelioma.

Authors:  Siti N Abdul Rahim; Gwo Y Ho; Jermaine I G Coward
Journal:  Transl Lung Cancer Res       Date:  2015-02

4.  The vascular landscape of human cancer.

Authors:  Benjamin M Kahn; Alfredo Lucas; Rohan G Alur; Maximillian D Wengyn; Gregory W Schwartz; Jinyang Li; Kathryn Sun; H Carlo Maurer; Kenneth P Olive; Robert B Faryabi; Ben Z Stanger
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

5.  Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells.

Authors:  R Eguchi; T Nakano; I Wakabayashi
Journal:  Oncogene       Date:  2016-06-27       Impact factor: 9.867

6.  Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy.

Authors:  Terence C Chua; Peng Yao; Javed Akther; David L Morris
Journal:  Pathol Oncol Res       Date:  2009-10-01       Impact factor: 3.201

Review 7.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Investigational approaches for mesothelioma.

Authors:  Veerle F Surmont; Eric R E van Thiel; Karim Vermaelen; Jan P van Meerbeeck
Journal:  Front Oncol       Date:  2011-08-22       Impact factor: 6.244

Review 9.  Intra-tumoural microvessel density in human solid tumours.

Authors:  J Hasan; R Byers; G C Jayson
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

10.  Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.

Authors:  Gauri R Varadhachary; Daniel M Halperin; Kanwal Raghav; Suyu Liu; Michael J Overman; Anneleis F Willett; Mark Knafl; Szu-Chin Fu; Anais Malpica; Seema Prasad; Richard E Royal; Christopher P Scally; Paul F Mansfield; Ignacio I Wistuba; Andrew P Futreal; Dipen M Maru; Luisa M Solis Soto; Edwin R Parra Cuentas; Honglei Chen; Pamela Villalobos; Anuj Verma; Armeen Mahvash; Patrick Hwu; Patricia Cortazar; Edward McKenna; Cindy Yun; Shannon Dervin; Katja Schulze; Walter C Darbonne; Ajaykumar C Morani; Scott Kopetz; Keith F Fournier; Scott E Woodman; James C Yao
Journal:  Cancer Discov       Date:  2021-07-14       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.